CEL SCI CORP
No SEC Form 4 filings for $CVM in the last 30 days.
See all $CVM insider activity →CEL SCI CORP (CVM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cvm_8k.htm 0000725363 false 0000725363 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da
CEL-SCI (NYSE American: CVM) said a manuscript with new Phase 3 IT-MATTERS Multikine data was accepted for publication in Oral Oncology. The company reported 5-year overall survival of 73% vs 45% in low PD-L1 oral cancer patients, and plans to start enrollment in a 212-patient confirmatory registration study.
CEL SCI CORP (CVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 cvm_ex11.htm PLACEMENT AGENCY AGREEMENT cvm_ex11.htm EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York June 14, 2026 ThinkEquity LLC 17 State Street, 41 st Floor New
Over the past 7 days, alphai's AI scored 1 news story mentioning CVM (CEL SCI CORP). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CVM coverage spans corporate actions, financial news and technology.
The filing confirms governance outcomes (board slate) and approval of equity compensation plans, which can affect dilution expectations but provides no new operational or financial guidance.
Journal acceptance reinforces the clinical narrative for Multikine and supports the upcoming 212-patient confirmatory registration enrollment.
The filing discloses a brokered equity offering structure (placement agent, fee, closing date), which can increase near-term dilution/financing risk.
CEL-SCI's recent capital raise indicates ongoing investment in Multikine, potentially supporting future growth. The company's stock may experience short-term stability or mild upward movement as investor confidence remains steady.
CEL-SCI's after-hours stock crash of approximately 38% is primarily driven by the announcement of a $10 million public offering priced below current market levels, indicating potential dilution and investor concern.
alphai scores every news story that mentions CVM with an AI model for sentiment and relevance, and aggregates insider trades from CEL SCI CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
CEL SCI CORP (CVM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cvm_8k.htm 0000725363 false 0000725363 2026-08-14 2026-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Da
2 min readCEL-SCI (NYSE American: CVM) said a manuscript with new Phase 3 IT-MATTERS Multikine data was accepted for publication in Oral Oncology. The company reported 5-year overall survival of 73% vs 45% in low PD-L1 oral cancer patients, and plans to start enrollment in a 212-patient confirmatory registration study.
4 min readCEL SCI CORP (CVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 cvm_ex11.htm PLACEMENT AGENCY AGREEMENT cvm_ex11.htm EXHIBIT 1.1 PLACEMENT AGENCY AGREEMENT between CEL-SCI CORPORATION and THINKEQUITY LLC 1 CEL-SCI CORPORATION PLACEMENT AGENCY AGREEMENT New York, New York June 14, 2026 ThinkEquity LLC 17 State Street, 41 st Floor New
3 min readCEL-SCI Corporation (NYSE American: CVM), a clinical stage cancer immunotherapy company, has closed a best-efforts public offering, raising approximately $7.2 million in gross proceeds from the sale of 6,000,000 shares of common stock at $1.20 per share. The company plans to use these funds for the continued development of its Multikine treatment, general corporate purposes, and working capital. ThinkEquity acted as the sole placement agent for the offering.
2 min readCEL-SCI Corporation CVM shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company's announcement of a $10 million public offering priced below current market levels. Check out the current price of CVM stock here.
3 min read
